Research Interests: Clinical Trials Navigation; Triple Negative Breast Cancer; Research Mentorship
Clinical Expertise: Breast Cancer, Stem Cell Transplant, Melanoma, Hematological Malignancies
Appointments and Affiliations:
Adjunct Professor, Biomedical Sciences, University of Windsor
Associate Professor, Western University
Core Principal Researcher, WE-SPARK Health Institute
Publications:
Ramanan, N., Malik, M.-n., Upneja, S., Farooq, H., Kulkarni, S., Gupta, R., Mathews, J., Nasser, A., Bocicariu, A., Arayan, L., Porter, L., Fifield, B.-A., Luo, R., Brackstone, M., & Hamm, C. (2025). Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis. Biomedicines, 13(5), 1100.
Abbas U, MacKenzie R, Khan U, Fatima R, Wang TF, Luo R, Hamm C, Cervi A. Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review. Res Pract Thromb Haemost. 2025 Jan 16;9(1):102684. doi: 10.1016/j.rpth.2025.102684. PMID: 39990096; PMCID: PMC11847241.
Patel R, Mathews J, Hamm C, Kulkarni S, Gupta R, Opperman T, Chiong JD, Nasser A. Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer. Current Oncology. 2025; 32(1):52.
Hossami, M.; Abdel-Nabi, R.; Zaib, F.; Touma, K.; Nassar, R.; Rim, S.C.; Paunic, M.; Hilal, O.; Gupta, P.; Hirmiz, R.; Hamm, C,: et al. Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program: A Cross-Sectional Study. Curr. Oncol. 2024, 31, 7144-7154. https://doi.org/10.3390/curroncol31110526
Ladak R, Fifield B, Porter L,, Hirmiz, K, Hamm, C (September 03, 2024) Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects. Cureus 16(9): e68576. doi:10.7759/cureus.68576
Fontyn S, Bai Y, Bolger S, Greco K, Wang T-F, Hamm C, Cervi A (2024). Inferior vena cava filter use at a large community hospital: a retrospective cohort study. Scientific Reports.
Awan A A, Saunders D, Pond G, Hamm C, Califaretti N, Mates M, Kumar V, Ibrahim M F K, Beltran-Bless A-A, Vandermeer L, Hilton J, Clemons M (2024). Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current Oncology.
Kashash D, McArthur E, Hamm C, Gupta R, Kanjeekal S, Jarrar M, Porter LA, Hudson JW, Renaud A, Woldie I. Presentation and Outcome of Patients with Multiple Myeloma (MM), Single Centre Experience from Windsor Essex Regional Cancer Centre. J Blood Med. 2024 Feb 26;15:101-111. doi: 10.2147/JBM.S434055. PMID: 38434928; PMCID: PMC10907128.
Hamm C, Cavallo-Medved D, Moudgil D, McGrath L, Huang J, Li Y, Stratton TW, Robinson T, Naccarato K, Sundquist S, Dancey J. Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator:A Cross-Sectional Analysis. Cancer Control. 2022 Jan-Dec; 29:10732748221130164. doi: 10.1177/10732748221130164. PMID: 36165718; PMCID: PMC9520135.
Zhou, A., Osman, A., Flores, G., Srikrishnaraj, D., Mohanty, J., Al Bader, R., Llancari, A., El-Hashemi, A., Elias, M., Mirza, K., Muldoon, M., Palazzolo, R., Zaib, F., Woldie, I., & Hamm, C. (2023). Critical illness in migrant workers in the Windsor-Essex Region: A descriptive analysis. International Journal of Environmental Research and Public Health, 20(16), 6587. https://doi.org/10.3390/ijerph20166587 Hamm, Caroline & Fifield, Bre-Anne & Amin, Kay & Kulkarni, Swati & Gupta, Rasna & Mathews, John & Ferraiuolo, Rosa-Maria & Al-Wahsh, Huda & Mailloux, Emily & Hussein, Abdulkadir & Porter, Lisa. (2022). A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. Medical Oncology. 39. 10.1007/s12032-021-01637-0.
Shum K, Hussein A, Hamm C. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database. Med Oncol. 2022 Sep 29;39(12):228. doi: 10.1007/s12032-022-01829-2. PMID: 36175693.
Ferraiuolo, RM., Fifield, BA., Hamm, C. et al. Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments. Breast Cancer Res Treat 196, 17–30 (2022).
McLaughlin K, Stojcevski A, Hussein A, Moudgil D, Woldie I, Hamm C. Patient vital signs in relation to ICU admission in treatment of acute leukemia: a retrospective chart review. Hematology. 2021 Dec;26(1):637-647. doi: 10.1080/16078454.2021.1966223. PMID: 34474663.
Hamm, Caroline. (2020). A retrospective single-center study investigating the clinical significance of grade in triple-negative breast cancer. Journal of Clinical Oncology. 38. e13108-e13108. 10.1200/JCO.2020.38.15_suppl.e13108.
|